Skip to main content

Table 3 The application of CRISPR/Cas9 in Rhabdomyosarcoma research

From: Applications of CRISPR/Cas9 in the research of malignant musculoskeletal tumors

Target Genes Cell lines CRISPR/Cas9 Applications Effects References
Pax3,Foxo1 Foxo1-inv+/+ myoblasts (mice)/primary myoblasts induce chromosomal translocation Pax3-Foxo1 chromosomal translocation ARSM model, no function research [82]
DMD CCL-136 RD knock out Produce DMD deletion - immortalized muscle cell line [83, 84]
DYSF TE671 knock out Myogenin↓,TSP-1 expression↑,membrane Repair ability ↓, [85]
Dozens genes JR1,RD knock out Validates oncogenes and tumors suppressors defined by iExCN tool [79]
HDAC1–10 genes (class I and II HDAC genes) 381 T, RD,SMS-CTR, Rh3,Rh5,Rh30 knock out cell growth↓,
myogenic differentiation↑,
xenografts tumor proliferation↓,differentiation↑,
[86]
PAX3-FOXO1 Dbt-MYCN / indP3F parental cellsa, recurrent tumour-derived cells. knock out Fail to form tumor in Dbt-MYCN/indP3F parental cells, form tumor in recurrent tumour-derived cells [80]
NRAS,HRAS 381 T,SMS-CTR ERMS cells knock out Cell viability↓,
apoptosis↑,
G1 phase arrest,
expression of key cell-cycle and DNA replication genes↓,
median survival of mice↑,xenografts tumor growth↓,
myogenic differentiation↑,
tumor regression
Perk expression↓
[87]
  1. Notes
  2. a:Dbt-MYCN/indP3F cells: immortalized human myoblasts containing constitutive MYCN and inducible PAX3–FOXO1; ↑:Up-regulation: ↓:Down-regulation